Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Atherosclerosis in 2016

Advances in new therapeutic targets for atherosclerosis

Nature Reviews Cardiology volume 14, pages 71–72 (2017)Cite this article

Subjects

In 2016, advances in atherosclerosis research were focused on the discovery and validation of new targets with genetic and mechanistic links to atherothrombotic heart disease. Novel targets include proteins involved in glycoprotein recognition and clearance, regulators of triglyceride-rich particle metabolism, inflammatory pathways that impair efferocytosis, and the gut microbiome.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Newly discovered mechanistic pathways leading to development and progression of atherosclerosis.

References

  1. Nioi, P. et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N. Engl. J. Med. 374, 2131–2141 (2016).

    Article  CAS  Google Scholar 

  2. Stitziel, N. O. et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N. Engl. J. Med. 374, 1134–1144 (2016).

    Article  CAS  Google Scholar 

  3. Dewey, F. E. et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N. Engl. J. Med. 374, 1123–1133 (2016).

    Article  CAS  Google Scholar 

  4. Zanoni, P. et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 351, 1166–1171 (2016).

    Article  CAS  Google Scholar 

  5. Nicholls, S. J. et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316, 2373–2384 (2016).

    Article  CAS  Google Scholar 

  6. Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86–90 (2016).

    Article  CAS  Google Scholar 

  7. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).

    Article  CAS  Google Scholar 

  8. Senthong, V. et al. Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. J. Am. Coll. Cardiol. 67, 2620–2628 (2016).

    Article  CAS  Google Scholar 

  9. Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111–124 (2016).

    Article  CAS  Google Scholar 

  10. Wang, Z. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585–1595 (2015).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

W.H.W.T. and S.L.H. are supported by grants from the National Institutes of Health and the Office of Dietary Supplements (R01HL103866, P20HL113452, R01DK106000, R01HL126827).

Author information

Authors and Affiliations

  1. W. H. Wilson Tang is at the Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.,

    W. H. Wilson Tang

  2. Stanley L. Hazen is at the Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.,

    Stanley L. Hazen

Authors
  1. W. H. Wilson Tang
    View author publications

    Search author on:PubMed Google Scholar

  2. Stanley L. Hazen
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Stanley L. Hazen.

Ethics declarations

Competing interests

S.L.H. is named as inventor on pending patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. He is also a paid consultant for Esperion and P&G, and has received research funds from Astra Zeneca, P&G, Pfizer Inc., Roche Diagnostics, and Takeda. S.L.H. has also received royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland HeartLab, Esperion, Frantz Biomarkers, LLC, and Siemens. W.H.W.T. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, W., Hazen, S. Advances in new therapeutic targets for atherosclerosis. Nat Rev Cardiol 14, 71–72 (2017). https://doi.org/10.1038/nrcardio.2016.216

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2016.216

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing